News | January 31, 2026
Glenmark reports robust Q3 FY26 performance, revenues surge 15% YoY
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
According to IQVIA sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market2 achieved annual sales of approximately $67.6 million
Hansoh Pharma will receive an upfront payment in the low double-digit millions
Glenmark's Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug
The positive outcome clears the way for Glenmark to resume commercial manufacturing at the site
Clinical studies conducted in India demonstrated that this nebulized triple therapy rapidly improves lung function and offers better control of breathlessness
Winlevi is authorized in EU for the treatment of acne vulgaris
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline
Glenmark will begin distribution in November 2025
Subscribe To Our Newsletter & Stay Updated
